Integral Diagnostics P/S 2024

Integral Diagnostics Aktienanalyse

What does Integral Diagnostics do?

Integral Diagnostics Ltd is an Australian company that has been providing medical imaging services for over 25 years. The company was founded in 1994 by Dr. Ian Kadish and a team of radiologists in Perth, Western Australia, offering radiology services to local clinics and hospitals. Over the years, Integral Diagnostics has expanded its services to provide imaging services nationwide. The business model of Integral Diagnostics is to deliver medical imaging to enable doctors and their patients to have a fast and accurate diagnosis. The company offers imaging services for a variety of medical specialties, including radiology, cardiology, obstetrics and gynecology, and neurology. They operate over 49 locations in Australia, many of which are in rural areas where access to medical care may be limited. Integral Diagnostics offers a wide range of products based on medical imaging. These include X-rays, mammography, ultrasound, CT scans, MRI scans, PET scans, and bone density scans. The company takes pride in being one of the few Australian medical imaging companies to offer a complete range of imaging services. Their services are conducted by qualified radiologists specialized in interpreting medical images. Integral Diagnostics also operates clinics for performing diagnostic and therapeutic procedures such as biopsies, drainages, and injections. These procedures are carried out by highly qualified radiologists to provide patients with faster and more accurate diagnoses. Integral Diagnostics is committed to quality assurance and has a comprehensive quality management system that is annually reviewed by independent auditors. The company is accredited by both the Australian Medical Association and the Australian National Accreditation Scheme (NATA). These accreditations recognize the high standards that Integral Diagnostics sets for delivering medical imaging services. One of Integral Diagnostics' recent activities is their use of artificial intelligence (AI) in image interpretation. The company has partnered with MaxQ AI, a leading provider of AI solutions for medical imaging. Through this partnership, Integral Diagnostics doctors can utilize the latest AI tools to improve their patients' diagnoses. Integral Diagnostics is a strong advocate for social justice and is dedicated to supporting disadvantaged communities in Australia. The company has partnered with nonprofit organizations such as the National Breast Cancer Foundation, The Smith Family, and the Friendship Foundation. Overall, Integral Diagnostics has undergone impressive growth over the past 25 years and is now a leading Australian medical imaging company. With a wide range of imaging services and a strong focus on quality and social responsibility, the company is well-positioned to continue its success in the future. Integral Diagnostics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Integral Diagnostics's P/S Ratio

Integral Diagnostics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Integral Diagnostics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Integral Diagnostics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Integral Diagnostics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Integral Diagnostics stock

What is the price-to-earnings ratio of Integral Diagnostics?

The price-earnings ratio of Integral Diagnostics is currently 1.21.

How has the price-earnings ratio of Integral Diagnostics changed compared to last year?

The price-to-earnings ratio of Integral Diagnostics has increased by -31.25% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Integral Diagnostics high compared to other companies?

Yes, the price-to-earnings ratio of Integral Diagnostics is high compared to other companies.

How does an increase in the price-earnings ratio of Integral Diagnostics affect the company?

An increase in the price-earnings ratio of Integral Diagnostics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Integral Diagnostics affect the company?

A decrease in the price-earnings ratio of Integral Diagnostics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Integral Diagnostics?

Some factors that influence the price-earnings ratio of Integral Diagnostics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Integral Diagnostics pay?

Over the past 12 months, Integral Diagnostics paid a dividend of 0.08 AUD . This corresponds to a dividend yield of about 2.77 %. For the coming 12 months, Integral Diagnostics is expected to pay a dividend of 0.08 AUD.

What is the dividend yield of Integral Diagnostics?

The current dividend yield of Integral Diagnostics is 2.77 %.

When does Integral Diagnostics pay dividends?

Integral Diagnostics pays a quarterly dividend. This is distributed in the months of April, September, March, September.

How secure is the dividend of Integral Diagnostics?

Integral Diagnostics paid dividends every year for the past 14 years.

What is the dividend of Integral Diagnostics?

For the upcoming 12 months, dividends amounting to 0.08 AUD are expected. This corresponds to a dividend yield of 2.73 %.

In which sector is Integral Diagnostics located?

Integral Diagnostics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Integral Diagnostics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Integral Diagnostics from 10/3/2024 amounting to 0.047 AUD, you needed to have the stock in your portfolio before the ex-date on 8/30/2024.

When did Integral Diagnostics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Integral Diagnostics in the year 2023?

In the year 2023, Integral Diagnostics distributed 0.086 AUD as dividends.

In which currency does Integral Diagnostics pay out the dividend?

The dividends of Integral Diagnostics are distributed in AUD.